Capecitabine and temozolomide (CAPTEM) is effective in metastatic well‐differentiated gastrointestinal neuroendocrine tumors

Objective The aim of this study was to investigate the outcomes and prognostic factors of patients with metastatic gastrointestinal neuroendocrine tumor (mGI‐NET) who were treated with capecitabine and temozolomide (CAPTEM) and somatostatin receptor ligand (octreotide or lanreotide). Methods Clinico...

Full description

Saved in:
Bibliographic Details
Published in:Journal of digestive diseases 2022-08, Vol.23 (8-9), p.493-499
Main Authors: Dogan, Izzet, Tastekin, Didem, Karabulut, Senem, Sakar, Burak
Format: Article
Language:English
Subjects:
Age
capecitabine
Disease control
Medical prognosis
Metastases
Metastasis
Multivariate analysis
Neuroendocrine tumors
Octreotide
Patients
prognosis
Somatostatin
Statistical analysis
Survival
temozolamide
Temozolomide
Thrombocytopenia
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2783-6d98839b1d6c3a625d82140ccbc6caf6f38c3d200f7be45cced1e55aad344bf33
cites cdi_FETCH-LOGICAL-c2783-6d98839b1d6c3a625d82140ccbc6caf6f38c3d200f7be45cced1e55aad344bf33
container_end_page 499
container_issue 8-9
container_start_page 493
container_title Journal of digestive diseases
container_volume 23
creator Dogan, Izzet
Tastekin, Didem
Karabulut, Senem
Sakar, Burak
description Objective The aim of this study was to investigate the outcomes and prognostic factors of patients with metastatic gastrointestinal neuroendocrine tumor (mGI‐NET) who were treated with capecitabine and temozolomide (CAPTEM) and somatostatin receptor ligand (octreotide or lanreotide). Methods Clinicopathological characteristics and treatment outcomes of 43 patients with mGI‐NET were retrospectively evaluated. Overall survival (OS) and progression‐free survival (PFS) were evaluated using Kaplan–Meier curve. Cox‐regression analysis was used to assess prognostic variables. Results There were 23 (53.5%) men and 20 women (46.5%) with a median age of 59 years (range 27–85 y). Patients were given octreotide (86.0%) or lanreotide (14.0%) with CAPTEM. In patients with well‐differentiated mGI‐NET, median PFS was 17.4 months, and the disease control rate was 71.1%. Patients with poorly differentiated mGI‐NET showed no response, and the median PFS was 4.5 months. Four (9.3%) discontinued the medication due to toxicity. Anemia (37.2%), thrombocytopenia (25.6%), and fatigue (16.3%) were the most prevalent adverse events. The 5‐year OS rate was 61.0% in all patients during a median follow‐up of 33.8 months. In multivariate analysis, age (P = 0.014) and tumor differentiation (P 
doi_str_mv 10.1111/1751-2980.13123
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2742927006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2742927006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2783-6d98839b1d6c3a625d82140ccbc6caf6f38c3d200f7be45cced1e55aad344bf33</originalsourceid><addsrcrecordid>eNqFULtOwzAUjRBIlMLMaokFhlA_8hyrtDykIhjKbDn2DXKVxMV2qcqA-AS-kS8hIagrd7mvc-49OkFwTvA16WJC0piENM-6lhHKDoLRfnK4r1N6HJw4t8I4TtIsGQUfhViD1F6UugUkWoU8NObd1KbRCtBlMX1azh-ukHYIqgqk12-AdIsa8MJ54bVEW6jr788vpbu9hdZr4UGhl25tjW49OK9bUaMWNtZAq4y0_Su_aYx1p8FRJWoHZ395HDzfzJfFXbh4vL0vpotQ0jRjYaLyLGN5SVQimUhorDJKIixlKRMpqqRimWSKYlylJUSxlKAIxLEQikVRWTE2Di6Gu2trXjedJL4yG9vJcpymEc1pinHSoSYDSlrjnIWKr61uhN1xgnlvMu9t5L2l_NfkjhEPjK2uYfcfnBez2cD7ARMhgh0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2742927006</pqid></control><display><type>article</type><title>Capecitabine and temozolomide (CAPTEM) is effective in metastatic well‐differentiated gastrointestinal neuroendocrine tumors</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Dogan, Izzet ; Tastekin, Didem ; Karabulut, Senem ; Sakar, Burak</creator><creatorcontrib>Dogan, Izzet ; Tastekin, Didem ; Karabulut, Senem ; Sakar, Burak</creatorcontrib><description>Objective The aim of this study was to investigate the outcomes and prognostic factors of patients with metastatic gastrointestinal neuroendocrine tumor (mGI‐NET) who were treated with capecitabine and temozolomide (CAPTEM) and somatostatin receptor ligand (octreotide or lanreotide). Methods Clinicopathological characteristics and treatment outcomes of 43 patients with mGI‐NET were retrospectively evaluated. Overall survival (OS) and progression‐free survival (PFS) were evaluated using Kaplan–Meier curve. Cox‐regression analysis was used to assess prognostic variables. Results There were 23 (53.5%) men and 20 women (46.5%) with a median age of 59 years (range 27–85 y). Patients were given octreotide (86.0%) or lanreotide (14.0%) with CAPTEM. In patients with well‐differentiated mGI‐NET, median PFS was 17.4 months, and the disease control rate was 71.1%. Patients with poorly differentiated mGI‐NET showed no response, and the median PFS was 4.5 months. Four (9.3%) discontinued the medication due to toxicity. Anemia (37.2%), thrombocytopenia (25.6%), and fatigue (16.3%) were the most prevalent adverse events. The 5‐year OS rate was 61.0% in all patients during a median follow‐up of 33.8 months. In multivariate analysis, age (P = 0.014) and tumor differentiation (P &lt; 0.001) were statistically significant factors for OS. Conclusions CAPTEM plus somatostatin receptor ligands were efficacious and well tolerated in individuals with well‐differentiated mGI‐NET. However, it was ineffective for those with poorly differentiated tumors. Age of 60 years or elder and poorly differentiated tumors were related to a poor patient prognosis. In this study, the efficacy of capecitabine and temozolomide (CAPTEM) combination in treating metastatic gastrointestinal neuroendocrine tumors (mGI‐NET) was evaluated. We showed that CAPTEM plus somatostatin receptor ligand (SRL) (octreotide or lanreotide) were effective and well tolerated in patients with well‐differentiated mGI‐NET, but was not effective in those with poorly differentiated mGI‐NET.</description><identifier>ISSN: 1751-2972</identifier><identifier>EISSN: 1751-2980</identifier><identifier>DOI: 10.1111/1751-2980.13123</identifier><language>eng</language><publisher>Melbourne: Wiley Publishing Asia Pty Ltd</publisher><subject>Age ; capecitabine ; Disease control ; Medical prognosis ; Metastases ; Metastasis ; Multivariate analysis ; Neuroendocrine tumors ; Octreotide ; Patients ; prognosis ; Somatostatin ; Statistical analysis ; Survival ; temozolamide ; Temozolomide ; Thrombocytopenia ; Toxicity</subject><ispartof>Journal of digestive diseases, 2022-08, Vol.23 (8-9), p.493-499</ispartof><rights>2022 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley &amp; Sons Australia, Ltd.</rights><rights>2022 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley &amp; Sons Australia, Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2783-6d98839b1d6c3a625d82140ccbc6caf6f38c3d200f7be45cced1e55aad344bf33</citedby><cites>FETCH-LOGICAL-c2783-6d98839b1d6c3a625d82140ccbc6caf6f38c3d200f7be45cced1e55aad344bf33</cites><orcidid>0000-0003-4740-9973 ; 0000-0003-3744-7044 ; 0000-0002-9522-9849 ; 0000-0003-1018-1119</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Dogan, Izzet</creatorcontrib><creatorcontrib>Tastekin, Didem</creatorcontrib><creatorcontrib>Karabulut, Senem</creatorcontrib><creatorcontrib>Sakar, Burak</creatorcontrib><title>Capecitabine and temozolomide (CAPTEM) is effective in metastatic well‐differentiated gastrointestinal neuroendocrine tumors</title><title>Journal of digestive diseases</title><description>Objective The aim of this study was to investigate the outcomes and prognostic factors of patients with metastatic gastrointestinal neuroendocrine tumor (mGI‐NET) who were treated with capecitabine and temozolomide (CAPTEM) and somatostatin receptor ligand (octreotide or lanreotide). Methods Clinicopathological characteristics and treatment outcomes of 43 patients with mGI‐NET were retrospectively evaluated. Overall survival (OS) and progression‐free survival (PFS) were evaluated using Kaplan–Meier curve. Cox‐regression analysis was used to assess prognostic variables. Results There were 23 (53.5%) men and 20 women (46.5%) with a median age of 59 years (range 27–85 y). Patients were given octreotide (86.0%) or lanreotide (14.0%) with CAPTEM. In patients with well‐differentiated mGI‐NET, median PFS was 17.4 months, and the disease control rate was 71.1%. Patients with poorly differentiated mGI‐NET showed no response, and the median PFS was 4.5 months. Four (9.3%) discontinued the medication due to toxicity. Anemia (37.2%), thrombocytopenia (25.6%), and fatigue (16.3%) were the most prevalent adverse events. The 5‐year OS rate was 61.0% in all patients during a median follow‐up of 33.8 months. In multivariate analysis, age (P = 0.014) and tumor differentiation (P &lt; 0.001) were statistically significant factors for OS. Conclusions CAPTEM plus somatostatin receptor ligands were efficacious and well tolerated in individuals with well‐differentiated mGI‐NET. However, it was ineffective for those with poorly differentiated tumors. Age of 60 years or elder and poorly differentiated tumors were related to a poor patient prognosis. In this study, the efficacy of capecitabine and temozolomide (CAPTEM) combination in treating metastatic gastrointestinal neuroendocrine tumors (mGI‐NET) was evaluated. We showed that CAPTEM plus somatostatin receptor ligand (SRL) (octreotide or lanreotide) were effective and well tolerated in patients with well‐differentiated mGI‐NET, but was not effective in those with poorly differentiated mGI‐NET.</description><subject>Age</subject><subject>capecitabine</subject><subject>Disease control</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Multivariate analysis</subject><subject>Neuroendocrine tumors</subject><subject>Octreotide</subject><subject>Patients</subject><subject>prognosis</subject><subject>Somatostatin</subject><subject>Statistical analysis</subject><subject>Survival</subject><subject>temozolamide</subject><subject>Temozolomide</subject><subject>Thrombocytopenia</subject><subject>Toxicity</subject><issn>1751-2972</issn><issn>1751-2980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFULtOwzAUjRBIlMLMaokFhlA_8hyrtDykIhjKbDn2DXKVxMV2qcqA-AS-kS8hIagrd7mvc-49OkFwTvA16WJC0piENM-6lhHKDoLRfnK4r1N6HJw4t8I4TtIsGQUfhViD1F6UugUkWoU8NObd1KbRCtBlMX1azh-ukHYIqgqk12-AdIsa8MJ54bVEW6jr788vpbu9hdZr4UGhl25tjW49OK9bUaMWNtZAq4y0_Su_aYx1p8FRJWoHZ395HDzfzJfFXbh4vL0vpotQ0jRjYaLyLGN5SVQimUhorDJKIixlKRMpqqRimWSKYlylJUSxlKAIxLEQikVRWTE2Di6Gu2trXjedJL4yG9vJcpymEc1pinHSoSYDSlrjnIWKr61uhN1xgnlvMu9t5L2l_NfkjhEPjK2uYfcfnBez2cD7ARMhgh0</recordid><startdate>202208</startdate><enddate>202208</enddate><creator>Dogan, Izzet</creator><creator>Tastekin, Didem</creator><creator>Karabulut, Senem</creator><creator>Sakar, Burak</creator><general>Wiley Publishing Asia Pty Ltd</general><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0003-4740-9973</orcidid><orcidid>https://orcid.org/0000-0003-3744-7044</orcidid><orcidid>https://orcid.org/0000-0002-9522-9849</orcidid><orcidid>https://orcid.org/0000-0003-1018-1119</orcidid></search><sort><creationdate>202208</creationdate><title>Capecitabine and temozolomide (CAPTEM) is effective in metastatic well‐differentiated gastrointestinal neuroendocrine tumors</title><author>Dogan, Izzet ; Tastekin, Didem ; Karabulut, Senem ; Sakar, Burak</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2783-6d98839b1d6c3a625d82140ccbc6caf6f38c3d200f7be45cced1e55aad344bf33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age</topic><topic>capecitabine</topic><topic>Disease control</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Multivariate analysis</topic><topic>Neuroendocrine tumors</topic><topic>Octreotide</topic><topic>Patients</topic><topic>prognosis</topic><topic>Somatostatin</topic><topic>Statistical analysis</topic><topic>Survival</topic><topic>temozolamide</topic><topic>Temozolomide</topic><topic>Thrombocytopenia</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dogan, Izzet</creatorcontrib><creatorcontrib>Tastekin, Didem</creatorcontrib><creatorcontrib>Karabulut, Senem</creatorcontrib><creatorcontrib>Sakar, Burak</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Journal of digestive diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dogan, Izzet</au><au>Tastekin, Didem</au><au>Karabulut, Senem</au><au>Sakar, Burak</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Capecitabine and temozolomide (CAPTEM) is effective in metastatic well‐differentiated gastrointestinal neuroendocrine tumors</atitle><jtitle>Journal of digestive diseases</jtitle><date>2022-08</date><risdate>2022</risdate><volume>23</volume><issue>8-9</issue><spage>493</spage><epage>499</epage><pages>493-499</pages><issn>1751-2972</issn><eissn>1751-2980</eissn><abstract>Objective The aim of this study was to investigate the outcomes and prognostic factors of patients with metastatic gastrointestinal neuroendocrine tumor (mGI‐NET) who were treated with capecitabine and temozolomide (CAPTEM) and somatostatin receptor ligand (octreotide or lanreotide). Methods Clinicopathological characteristics and treatment outcomes of 43 patients with mGI‐NET were retrospectively evaluated. Overall survival (OS) and progression‐free survival (PFS) were evaluated using Kaplan–Meier curve. Cox‐regression analysis was used to assess prognostic variables. Results There were 23 (53.5%) men and 20 women (46.5%) with a median age of 59 years (range 27–85 y). Patients were given octreotide (86.0%) or lanreotide (14.0%) with CAPTEM. In patients with well‐differentiated mGI‐NET, median PFS was 17.4 months, and the disease control rate was 71.1%. Patients with poorly differentiated mGI‐NET showed no response, and the median PFS was 4.5 months. Four (9.3%) discontinued the medication due to toxicity. Anemia (37.2%), thrombocytopenia (25.6%), and fatigue (16.3%) were the most prevalent adverse events. The 5‐year OS rate was 61.0% in all patients during a median follow‐up of 33.8 months. In multivariate analysis, age (P = 0.014) and tumor differentiation (P &lt; 0.001) were statistically significant factors for OS. Conclusions CAPTEM plus somatostatin receptor ligands were efficacious and well tolerated in individuals with well‐differentiated mGI‐NET. However, it was ineffective for those with poorly differentiated tumors. Age of 60 years or elder and poorly differentiated tumors were related to a poor patient prognosis. In this study, the efficacy of capecitabine and temozolomide (CAPTEM) combination in treating metastatic gastrointestinal neuroendocrine tumors (mGI‐NET) was evaluated. We showed that CAPTEM plus somatostatin receptor ligand (SRL) (octreotide or lanreotide) were effective and well tolerated in patients with well‐differentiated mGI‐NET, but was not effective in those with poorly differentiated mGI‐NET.</abstract><cop>Melbourne</cop><pub>Wiley Publishing Asia Pty Ltd</pub><doi>10.1111/1751-2980.13123</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-4740-9973</orcidid><orcidid>https://orcid.org/0000-0003-3744-7044</orcidid><orcidid>https://orcid.org/0000-0002-9522-9849</orcidid><orcidid>https://orcid.org/0000-0003-1018-1119</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1751-2972
ispartof Journal of digestive diseases, 2022-08, Vol.23 (8-9), p.493-499
issn 1751-2972
1751-2980
language eng
recordid cdi_proquest_journals_2742927006
source Wiley-Blackwell Read & Publish Collection
subjects Age
capecitabine
Disease control
Medical prognosis
Metastases
Metastasis
Multivariate analysis
Neuroendocrine tumors
Octreotide
Patients
prognosis
Somatostatin
Statistical analysis
Survival
temozolamide
Temozolomide
Thrombocytopenia
Toxicity
title Capecitabine and temozolomide (CAPTEM) is effective in metastatic well‐differentiated gastrointestinal neuroendocrine tumors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T23%3A31%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Capecitabine%20and%20temozolomide%20(CAPTEM)%20is%20effective%20in%20metastatic%20well%E2%80%90differentiated%20gastrointestinal%20neuroendocrine%20tumors&rft.jtitle=Journal%20of%20digestive%20diseases&rft.au=Dogan,%20Izzet&rft.date=2022-08&rft.volume=23&rft.issue=8-9&rft.spage=493&rft.epage=499&rft.pages=493-499&rft.issn=1751-2972&rft.eissn=1751-2980&rft_id=info:doi/10.1111/1751-2980.13123&rft_dat=%3Cproquest_cross%3E2742927006%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2783-6d98839b1d6c3a625d82140ccbc6caf6f38c3d200f7be45cced1e55aad344bf33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2742927006&rft_id=info:pmid/&rfr_iscdi=true